These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 10652956

  • 1. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women.
    Dresner-Pollak R, Mayer M, Hochner-Celiniker D.
    Calcif Tissue Int; 2000 Feb; 66(2):104-7. PubMed ID: 10652956
    [Abstract] [Full Text] [Related]

  • 2. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F.
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [Abstract] [Full Text] [Related]

  • 3. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ, Chesnut CH, Mallinak NJ.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [Abstract] [Full Text] [Related]

  • 4. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarikoski S.
    Osteoporos Int; 2000 Jun; 11(3):211-8. PubMed ID: 10824236
    [Abstract] [Full Text] [Related]

  • 5. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, Saarikoski S.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [Abstract] [Full Text] [Related]

  • 6. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

  • 7. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

  • 8. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M, Härmä K, Komulainen M, Kiviniemi V, Kröger H, Honkanen R, Alhava E, Jurvelin J, Saarikoski S.
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [Abstract] [Full Text] [Related]

  • 9. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR.
    Maturitas; 2008 Jan 20; 59(1):2-6. PubMed ID: 18063490
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R.
    J Clin Endocrinol Metab; 1996 Oct 20; 81(10):3487-91. PubMed ID: 8855790
    [Abstract] [Full Text] [Related]

  • 11. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
    Chesnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ.
    Am J Med; 1997 Jan 20; 102(1):29-37. PubMed ID: 9209198
    [Abstract] [Full Text] [Related]

  • 12. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.
    Tiraş MB, Noyan V, Yildiz A, Yildirim M, Daya S.
    Hum Reprod; 2000 Oct 20; 15(10):2087-92. PubMed ID: 11006178
    [Abstract] [Full Text] [Related]

  • 13. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages.
    Evans SF, Davie MW.
    Clin Endocrinol (Oxf); 1996 Jan 20; 44(1):79-84. PubMed ID: 8706298
    [Abstract] [Full Text] [Related]

  • 14. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K.
    Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472
    [Abstract] [Full Text] [Related]

  • 15. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    Ann Med; 2003 Jan 20; 35(4):282-8. PubMed ID: 12846271
    [Abstract] [Full Text] [Related]

  • 16. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
    Franklyn JA, Betteridge J, Holder R, Sheppard MC.
    Thyroid; 1995 Oct 20; 5(5):359-63. PubMed ID: 8563472
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul 20; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
    Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C.
    J Clin Endocrinol Metab; 2001 Feb 20; 86(2):755-60. PubMed ID: 11158042
    [Abstract] [Full Text] [Related]

  • 19. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 Feb 20; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 20. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA.
    J Bone Miner Res; 2006 Feb 20; 21(2):283-91. PubMed ID: 16418784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.